SCHEMBL8093719

SCHEMBL8093719

COc1cc(F)c(F)c(F)c1F

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TUBB1 Q9H4B7 4/20 0.44
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
HTR2A P28223 2/20 0.35
HTR2C P28335 2/20 0.35
HTR2B P41595 2/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
PTGS2 P35354 1/20 0.34
KDM1A O60341 3/20 0.34
NFE2L2 Q16236 2/20 0.33
PTGES O14684 1/20 0.33
ALOX5 P09917 1/20 0.33
PTGS1 P23219 1/20 0.33
STAT3 P40763 1/20 0.33
ACHE P22303 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL29739052 0.97 TUBB1 (0.42) TUBB1LMNAMAPK1HTTRAB9A
Bromide SCHEMBL29189119 0.95 TUBB1 (0.41) TUBB1LMNAMAPK1HTTRAB9A
SCHEMBL167017 0.80 TUBB1 (0.41) TUBB1LMNAMAPK1HTTRAB9A
SCHEMBL8885005 0.80 TUBB1 (0.41) TUBB1LMNAMAPK1HTTRAB9A
SCHEMBL11160603 0.80 ACHE (0.41) TUBB1LMNAMAPK1HTTRAB9A
SCHEMBL7976367 0.80 TUBB1 (0.41) TUBB1LMNAMAPK1HTTRAB9A
SCHEMBL20149289 0.80 MAPT (0.39) TUBB1LMNAMAPK1HTTRAB9A
SCHEMBL28977384 0.80 TUBB1 (0.39) TUBB1LMNAMAPK1HTTRAB9A
SCHEMBL24436695 0.78 PTGS2 (0.44) TUBB1LMNACYP3A4MAPTPTGS2
SCHEMBL9678363 0.78 TUBB1 (0.40) TUBB1LMNAMAPK1HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114671762-B Fluorine-containing bi-xylylene methacrylate cross-linking agent and preparation method thereof 长春市兆兴新材料技术有限责任公司 2024-03-19 CN claimed
CN-114671762-A Fluorine-containing biphenyl dimethacrylate crosslinking agent and preparation method thereof 长春市兆兴新材料技术有限责任公司 2022-06-28 CN claimed
EP-0488861-A1 Process for the preparation of alkoxylated aromatic compounds RHONE-POULENC CHIMIE (FR) 1992-06-03 EP claimed
US-12559454-B2 Benzenesulfonamide derivatives and uses thereof 2692372 ONTARIO, INC. (CA) 2026-02-24 US disclosed
CN-119500004-A Production system of oxyfluoro cyclic ester 江西省驰邦药业有限公司 2025-02-25 CN disclosed
US-20240092756-A1 METHODS AND COMPOSITION FOR KRAS MODIFICATIONS DUNAD THERAPEUTICS LTD. (GB) 2024-03-21 US disclosed
CN-114671762-B Fluorine-containing bi-xylylene methacrylate cross-linking agent and preparation method thereof 长春市兆兴新材料技术有限责任公司 2024-03-19 CN disclosed
US-20230359119-A1 RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-11-09 US disclosed
US-11780935-B2 Mutant antibodies and conjugation thereof PFIZER HEALTHCARE IRELAND (IE) 2023-10-10 US disclosed
EP-4247787-A2 METHODS AND COMPOSITION FOR KRAS MODIFICATIONS 2692372 Ontario, Inc. (CA) 2023-09-27 EP disclosed
CN-116745264-A Methods and compositions for KRAS modification 2692372安大略公司 2023-09-12 CN disclosed
WO-2022075383-A1 ESTER COMPOUND AND RESIN COMPOSITION 味の素株式会社 2022-04-14 WO disclosed
WO-2021099842-A1 PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 ONTARIO INC. (CA) 2021-05-27 WO disclosed
US-20210147576-A1 MUTANT ANTIBODIES AND CONJUGATION THEREOF PFIZER HEALTHCARE IRELAND (IE) 2021-05-20 US disclosed
WO-2021009568-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 ONTARIO, INC. (CA) 2021-01-21 WO disclosed
WO-2019149116-A1 METHOD FOR PREPARING CONJUGATE 四川科伦博泰生物医药股份有限公司 2019-08-08 WO disclosed
WO-2013105013-A1 MUTANT ANTIBODIES AND CONJUGATION THEREOF COVX TECHNOLOGIES IRELAND LIMITED (IE) 2013-07-18 WO disclosed
WO-2012007896-A1 MULTIFUNCTIONAL ANTIBODY CONJUGATES COVX TECHNOLOGIES IRELAND, LTD. (IE) 2012-01-19 WO disclosed
JP-2000156243-A NONAQUEOUS ELECTROLYTE BATTERY SONY CORP 2000-06-06 JP disclosed
EP-0488861-A1 Process for the preparation of alkoxylated aromatic compounds RHONE-POULENC CHIMIE (FR) 1992-06-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092756-A1 METHODS AND COMPOSITION FOR KRAS MODIFICATIONS KRAS, NRAS, HRAS TUBB1 3278/4885LMNA 1904/4885MAPK1 1706/4885
US-20210147576-A1 MUTANT ANTIBODIES AND CONJUGATION THEREOF IGLV6-57, IGSF11, F13B TUBB1 360/4885LMNA 752/4885MAPK1 4397/4885
US-11780935-B2 Mutant antibodies and conjugation thereof IGLV6-57, IGSF11, F13B TUBB1 365/4885LMNA 737/4885MAPK1 4386/4885
US-12559454-B2 Benzenesulfonamide derivatives and uses thereof NR2E1, NR2C2, NR3C1 TUBB1 2124/4885LMNA 1384/4885MAPK1 3317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.